Cargando…

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature

Oral mucosal melanoma (OMM) is an aggressive malignant tumor derived from melanocytes in the oral cavity. The genetic etiology of OMM has not been extensively investigated to date. In the present study, the aim was to detect novel gene mutations in patients with OMM. Mutation analysis of KIT, BRAF a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Feng, Zhang, Qian, Wang, Yanjin, Wang, Siwen, Feng, Shawein, Qi, Liyuan, Li, Xuefen, Ding, Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958699/ https://www.ncbi.nlm.nih.gov/pubmed/29805686 http://dx.doi.org/10.3892/ol.2018.8558

Ejemplares similares

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
por: Wróblewska, Joanna P., et al.
Publicado: (2021)

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population
por: Gutiérrez-Castañeda, Luz D., et al.
Publicado: (2020)

Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
por: Gutiérrez-Castañeda, Luz Dary, et al.
Publicado: (2020)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study
por: Taskın, Orhun Cig, et al.
Publicado: (2023)

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center
por: Ren, Min, et al.
Publicado: (2022)

FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome
por: Gardberg, Maria, et al.
Publicado: (2016)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status
por: Casadonte, Rita, et al.
Publicado: (2023)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
por: Shackelford, Rodney, et al.
Publicado: (2014)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
por: Heppt, Markus V., et al.
Publicado: (2017)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China
por: Ma, Xuhui, et al.
Publicado: (2017)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy
por: McGrail, Kimberley, et al.
Publicado: (2022)

Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
por: Conway, Caroline, et al.
Publicado: (2010)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
por: Satzger, I, et al.
Publicado: (2008)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
por: Emelyanova, Marina, et al.
Publicado: (2017)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015)

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
por: Raaijmakers, Marieke I. G., et al.
Publicado: (2016)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Fakhruddin, Najla, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3t7t5jotupo4crmda9ll9ml3nk